1. Effects of four Chinese herbal extracts on drug-sensitive and multidrug-resistant small-cell lung carcinoma cells

   • David Sadava
   • Julie Ahn
   • Susan E. Kane

   Original Article Pages: 261 - 266

2. Dihydropyrimidine dehydrogenase expression in preoperative biopsy and surgically resected specimens of gastric carcinoma

   • Hiroaki Nozawa
   • Hajime Tsukui
   • Takayoshi Sekikawa

   Original Article Pages: 267 - 273

3. Effects of paclitaxel, cyclophosphamide, ifosfamide, tamoxifen and cyclosporine on the metabolism of methoxymorpholinodoxorubicin in human liver microsomes

   • Dominique Beulz-Riché
   • Jacques Robert
   • Damrong Ratanasavanh

   Original Article Pages: 274 - 280

4. XK469, a novel antitumor agent, inhibits signaling by the MEK/MAPK signaling pathway

   • Hong Lin
   • Balanehru Subramanian
   • Ben D. Chen

   Original Article Pages: 281 - 286

5. Population pharmacokinetics of the novel anticancer agent KRN7000

   • Mirjam Crul
   • Ron A. Mathôt
   • Jos H. Beijnen

   Original Article Pages: 287 - 293

6. Alterations in intestinal permeability following the intensified polydrug-chemotherapy IFADIC (ifosfamide, Adriamycin, dacarbazine)

   • Barbara Fazeny-Dörner
   • Mario Veitl
   • Christine Marosi

   Original Article Pages: 294 - 298

7. Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer

   • Edgardo Rivera
   • Vicente Valero
   • Gabriel N. Hortobagyi

   Original Article Pages: 299 - 302

8. Low dose–high dose: what is the right dose? Pharmacokinetic modeling of etoposide

   • Gudrun Würthwein
   • Joachim Boos

   Original Article Pages: 303 - 308

9. Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study

   • Norman E. Sládek
   • Rahn Kollander
   • David T. Kiang

   Original Article Pages: 309 - 321

10. P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel

    • Yoshimitsu Kimura
    • Jun Aoki
    • Osamu Nakanishi

    Original Article Pages: 322 - 328

11. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines

    • Valérie Pavillard
    • Cécile Agostini
    • Jacques Robert

    Original Article Pages: 329 - 335

12. Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice

    • Lalitha Iyer
    • Jacqueline Ramírez
    • Ulrich Mayer

    Original Article Pages: 336 - 341

13. A phase II trial of methotrexate-human serum albumin (MTX-HSA) in patients with metastatic renal cell carcinoma who progressed under immunotherapy

    • A. Vis
    • A. van der Gaast
    • G. Mickisch

    Clinical Trial Report Pages: 342 - 345